Medtronic Q3 FY25: A Journey Through Innovation and Data-Driven Insights
Medtronic’s Q3 FY25 performance showcases resilience with $8.3 billion revenue, strong growth in Cardiac Ablation and Diabetes, and strategic advancements despite market headwinds.
